ArcticZymes Technologies ASA Publishes Innovative Research on Novel RNA Restriction Enzyme, Paving the Way for Precision RNA Manipulation

16 Sep 2024 08:48 CEST

Tromsø, Norway, September 16 2024 - ArcticZymes Technologies ASA (OSE:AZT), a
leading developer and manufacturer of high-quality enzymes for molecular
research, diagnostics, and therapeutics, is thrilled to announce the publication
of a research paper in the prestigious international peer-reviewed journal
Nucleic Acid Research. The paper, entitled "Using nucleolytic toxins as
restriction enzymes enables new RNA applications," showcases the unique features
and potential applications of a novel RNA restriction enzyme called ET-N1
(EcoToxN1).

Revolutionizing RNA Fragmentation: The patent-pending ET-N1 enzyme technology
represents a significant advancement in the field of RNA research, enabling
precise and controlled fragmentation of RNA molecules. This innovative tool
opens up new possibilities for analyzing and synthesizing RNA, paving the way
for the development of cutting-edge methodologies in the rapidly evolving field
of RNA research and therapeutics.

Unique Capabilities: What sets ET-N1 apart from other commercialized enzymes is
its ability to act as "molecular scissors," offering functions that no other
enzyme can currently match. With the development of further variants,
ArcticZymes Technologies ASA is poised to revolutionize the landscape of RNA
modulation tools, empowering researchers and industry partners to push the
boundaries of scientific discovery and therapeutic innovation.

Collaborative Effort: The research paper, authored by Rothweiler et al., is the
result of a collaborative effort between ArcticZymes Technologies ASA and
esteemed academic and research institutions, including the University of Tromsø,
Norway, the Indian Institute of Science, Bangalore, India, and SINTEF Industry,
Trondheim, Norway. This collaborative endeavor was made possible through the
support of the Norwegian Research Council's innovation grant "AdEPT - Advanced
Enzymes for Precision Therapeutics."

Driving Progress and Innovation: Emphasizing ArcticZymes commitment to driving
progress and innovation in the field, CEO Michael Akoh comments: "Through
dissemination of our research findings in peer-reviewed journals, ArcticZymes
aims to elevate awareness of our cutting-edge products and stimulate the
emergence of disruptive technologies. We are committed to driving forward
progress in the field, providing enzymes that unlock new discoveries enabling
our partners' development of tomorrows innovative technologies".

Read the paper here: Using nucleolytic toxins as restriction enzymes enables new
RNA applications | Nucleic Acids Research | Oxford Academic
(oup.com) (https://academic.oup.com/nar/advance
-article/doi/10.1093/nar/gkae779/7756578?searchresult=1)

For more information, please contact:

ArcticZymes Technologies ASA

CEO, Michael B. Akoh Tel: +46 (0) 70 262 37 15

CFO, Børge Sørvoll Tel: +47 95 29 01 87

ir@arcticzymes.com

About ArcticZymes Technologies ASA:

ArcticZymes Technologies ASA (OSE: AZT) is a global leader in supplying best-in
-class enzyme technologies to commercial partners who developing therapeutics,
in vitro diagnostics, and molecular research kit products. Our mission is to
make our customer's lives easier by unlocking new solutions to enhance quality
of life and create a more sustainable, healthy world.

More information:
Access the news on Oslo Bors NewsWeb site

627808_20240916_ET_N1_publication_Press_Release.pdf